BioCardia (BCDA) Stock Price, News & Analysis

Company Overview

BioCardia, Inc. is a biotechnology company focused on developing regenerative cell therapies and related delivery systems for cardiovascular diseases. The company’s programs are designed to repair or improve heart tissue and function in patients with conditions such as chronic heart failure and refractory angina caused by coronary artery disease.

BioCardia’s lead programs include CardiAMP Cell Therapy, an investigational autologous treatment that uses a patient’s own bone marrow-derived cells, and CardiALLO, an investigational allogeneic cell therapy based on donor-derived cells. The company also develops catheter-based systems and procedures intended to deliver therapeutic cells to targeted areas of the heart. These products remain investigational and are being evaluated in clinical studies rather than marketed as broadly approved treatments.

Founded in 2002 and headquartered in Sunnyvale, California, BioCardia conducts clinical development activities in the United States and has worked with medical centers and research collaborators internationally. The company is led by Peter Altman, who serves as president and chief executive officer.

Key Stats

• Today's Range: $1.02 to $1.08
• 50-Day Range: $0.83 to $1.25
• 52-Week Range: $0.75 to $1.80
• Volume: 101,925 shs
• Average Volume: 374,698 shs
• Market Capitalization: $15.75 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $25.00
• Consensus Rating: Hold

BioCardia Stock Analysis - MarketRank™

BioCardia scored higher than 76% of companies evaluated by MarketBeat, and ranked 165th out of 882 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Hold

Consensus Rating

BioCardia has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.

Upside Potential

BioCardia has a consensus price target of $25.00, representing about 2,303.8% upside from its current price of $1.04.

Amount of Analyst Coverage

BioCardia has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for BioCardia are expected to grow in the coming year, from ($0.71) to ($0.58) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of BioCardia is -1.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of BioCardia is -1.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

BioCardia has a P/B Ratio of 13.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.95% of the float of BioCardia has been sold short.

Short Interest Ratio / Days to Cover

BioCardia has a short interest ratio ("days to cover") of 1.27, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in BioCardia has recently decreased by 28.31%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BioCardia does not currently pay a dividend.

Dividend Growth

BioCardia does not have a long track record of dividend growth.

News and Social Media

• Score: 1.6 / 5
• News Sentiment: 0.60

News Sentiment

BioCardia has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for BioCardia this week, compared to 3 articles on an average week.

Search Interest

Only 1 people have searched for BCDA on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added BioCardia to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 3.7 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $14,567.00 in company stock, which represents 0.0925% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, BioCardia insiders have bought more of their company's stock than they have sold. Specifically, they have bought $14,567.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

17.40% of the stock of BioCardia is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

20.57% of the stock of BioCardia is held by institutions.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 10/11/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:BCDA
• CIK: 925741
• Web: www.biocardia.com
• Phone: (650) 226-0123
• Fax: 310-861-5299
• Employees: 21
• Year Founded: 2002

Price Target and Rating

• Average Price Target for BioCardia: $25.00
• High Price Target: $25.00
• Low Price Target: $25.00
• Potential Upside/Downside: +2,303.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.64)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$8.23 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -569.36%
• Return on Assets: -183.15%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.09
• Quick Ratio: 2.09

Sales & Book Value

• Annual Sales: $60 thousand
• Price / Sales: 262.43
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.08 per share
• Price / Book: 13.00

Miscellaneous

• Outstanding Shares: 15,140,000
• Free Float: 12,505,000
• Market Cap: $15.75 million
• Optionable: Optionable
• Beta: 0.62